WallStSmart
CRDL

Cardiol Therapeutics Inc Class A

NASDAQ: CRDL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC

$1.35
-3.48% today

Updated 2026-06-05

Market cap
$130.26M
P/E ratio
P/S ratio
1,014.87x
EPS (TTM)
$-0.28
Dividend yield
52W range
$1 – $2
Volume
0.7M

Cardiol Therapeutics Inc Class A (CRDL) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$0.00$0.00$78760.00$62267.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)-20.9%-100.0%
Cost of revenue$53341.00$91492.00$116114.00$180171.00$174264.00$162226.00$187383.00
Gross profit$-53341.00$-91492.00$-116114.00$-180171.00$-111997.00$-162226.00$-187383.00
Gross margin-228.8%-179.9%
R&D$441257.00$1.53M$2.72M$8.25M$8.59M$13.99M$10.73M$14.01M$14.02M
SG&A$1.10M$5.87M$10.45M$9.95M$27.87M$22.37M$15.56M$25.89M$20.20M
Operating income$-1.59M$-7.39M$-10.89M$-16.24M$-30.57M$-30.49M$-22.47M$-40.28M$-34.32M
Operating margin-20620.3%-49092.4%
EBITDA$-1.50M$-7.30M$-10.44M$-16.02M$-24.84M$-22.66M$-21.04M$-36.52M$-33.72M
EBITDA margin-20342.2%-39891.0%
EBIT$-1.56M$-7.39M$-10.55M$-16.20M$-25.01M$-22.82M$-21.22M$-36.68M$-33.82M
Interest expense$60562.00$663373.00$621.00$0.00$0.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-1.66M$-15.89M$-10.55M$-16.20M$-25.01M$-22.82M$-21.22M$-36.68M$-33.82M
Net income growth (YoY)-856.9%+33.6%-53.5%-54.4%+8.8%+7.0%-72.8%+7.8%
Profit margin-20570.9%-40170.9%

Frequently asked questions

How much free cash flow does CRDL generate?

CRDL produced $-23.88M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is CRDL's balance sheet healthy?

CRDL holds $21.42M in cash and equivalents against — in long-term debt, on $17.88M of shareholder equity. That debt is best read against the cash flow the business throws off each year.